Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503483 | 0.92 | RAF1 (0.31) | TYK2 | |
| SCHEMBL6491690 | 0.83 | HTR2C (0.36) | TYK2PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL6503481 | 0.82 | CCR3 (0.31) | PIK3CDPIK3CALRRK2MALT1 | |
| SCHEMBL6490568 | 0.78 | CCR3 (0.32) | — | |
| SCHEMBL6504219 | 0.77 | PIK3CA (0.36) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6810852 | 0.76 | HTR2C (0.32) | — | |
| SCHEMBL6810658 | 0.75 | TYK2 (0.35) | TYK2 | |
| SCHEMBL6502965 | 0.73 | HTR2A (0.36) | — | |
| SCHEMBL6490580 | 0.73 | DRD2 (0.34) | — | |
| SCHEMBL6810428 | 0.73 | DRD2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | TYK2 1181/4885PIK3CD 2117/4885PIK3R1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.